Skip to main content

Advertisement

Fig. 5 | Gynecological Surgery

Fig. 5

From: HMG-CoA reductase inhibitor lovastatin upregulates plasminogen activator production through RhoA-signaling in peritoneal cell line Met5A

Fig. 5

The proposed effects of lovastatin on plasminogen activator (PA) upregulation. Hydroxymethylglutaryl (HMG)-CoA reductase stimulates the synthesis of mevalonate and isoprenoid intermediate geranylgeranyl pyrophosphate (GGPP). GGPP catalyzes the geranylgeranylation of RhoA, a key step in the translocation of RhoA from cytoplasm to the plasma membrane. The active membrane-bound RhoA initiates downstream signaling via Rho kinase to downregulate PA. HMG-CoA inhibitor lovastatin reduces RhoA activation and fibrinolytic activity by preventing the membrane localization and activation of PA production

Back to article page